LianBio (NASDAQ:LIAN – Get Free Report) and Kaleido Biosciences (NASDAQ:KLDO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.
Earnings & Valuation
This table compares LianBio and Kaleido Biosciences’ top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
LianBio | N/A | N/A | -$110.29 million | ($0.81) | -0.37 |
Kaleido Biosciences | $1.10 million | 0.00 | -$95.48 million | ($2.24) | N/A |
Kaleido Biosciences has higher revenue and earnings than LianBio. LianBio is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
Risk & Volatility
LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.
Profitability
This table compares LianBio and Kaleido Biosciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
LianBio | N/A | -33.17% | -30.19% |
Kaleido Biosciences | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for LianBio and Kaleido Biosciences, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
LianBio | 1 | 1 | 1 | 0 | 2.00 |
Kaleido Biosciences | 0 | 0 | 0 | 0 | N/A |
LianBio presently has a consensus target price of $5.33, suggesting a potential upside of 1,677.78%.
Summary
Kaleido Biosciences beats LianBio on 7 of the 10 factors compared between the two stocks.
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
About Kaleido Biosciences
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.